Do Traders Think Pyxis Oncology Inc (PYXS) Can Keep Climbing Tuesday?

Pyxis Oncology Inc (PYXS) stock has risen 6.13% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Pyxis Oncology Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on PYXS!

See Full PYXS Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With PYXS Stock Today?

Pyxis Oncology Inc (PYXS) stock is trading at $2.25 as of 12:32 PM on Tuesday, Sep 5, a decline of -$0.07, or -3.02% from the previous closing price of $2.32. The stock has traded between $2.25 and $2.46 so far today. Volume today is elevated. So far 237,400 shares have traded compared to average volume of 170,508 shares. To see InvestorsObserver's Sentiment Score for Pyxis Oncology Inc click here.

More About Pyxis Oncology Inc

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Click Here to get the full Stock Report for Pyxis Oncology Inc stock.